Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Internalized-arginylglycylaspartic Acid Cyclic Peptide

Peptide · Modulator of integrin alpha-v beta-3 and integrin alpha-v beta-5 · developed by Lisata Therapeutics

Phase 1 Most advanced trial (none active)
LSTA Developer
1 Registered trials

What is Internalized-arginylglycylaspartic Acid Cyclic Peptide?

CEND-1 (iRGD) is a cyclic nine-amino-acid peptide containing an RGD motif that binds alphav beta3 and alphav beta5 integrins on tumor endothelium. After tumor-specific protease cleavage, its exposed CendR motif binds neuropilin-1, increasing tumor vascular permeability and tissue penetration of co-administered or conjugated agents. It is studied in pancreatic ductal adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CEND-1
Drug type
Peptide
Targets
integrin alpha-v beta-3, integrin alpha-v beta-5, neuropilin-1 (NRP1) (secondary target)
Mechanism
Modulator of integrin alpha-v beta-3 and integrin alpha-v beta-5
Pathways
tumor vascular permeability, tumor penetration
Therapy area
Oncology
Developer
Lisata Therapeutics, Inc. (LSTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
Z8MXU5GH4Q

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03517176 Phase 1 Pancreatic Cancer Completed LSTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic CancerPancreatic Ductal Adenocarcinoma

More from Lisata Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.

Follow LSTA, the company behind Internalized-arginylglycylaspartic Acid Cyclic Peptide

See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LSTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.